Glaukos Corporation (NYSE: GKOS), an ophthalmic medical
technology and pharmaceutical company focused on novel therapies
for the treatment of glaucoma, corneal disorders and retinal
diseases, announced today that its technologies will be featured in
various scientific programming at the American Academy of
Ophthalmology (AAO) annual meeting, being held November 3-6, 2023
in San Francisco, CA. Glaukos will be exhibiting onsite at booth
#1630.
Key Glaucoma Presentations:
Saturday, November 4, 2023, at 10:00 – 10:30 a.m. PT
- Jason Bacharach, MD IOP at Month 3 with Travoprost
Intraocular Implant vs. IOP at Screening While on Prostaglandin
Analog Monotherapy
Key Glaucoma Posters:
- Mark J. Gallardo, MD Safety of Travoprost Intraocular
Implant Administration on the Corneal Endothelium
- Fritz H. Hengerer, MD Trabecular Micro-Bypass + Cataract
Surgery Shows 7-Year Efficacy and Safety in Both Combined and
Stand-Alone Usage
- Daniel J. Hu, BA Efficacy of Combined Trabecular
Micro-Bypass and Goniotomy in Patients With OAG
- Joshua Kim, MD IOP Controlled in Greater Percentage of
Subjects with Travoprost Intraocular Implant Compared with Topical
Timolol at 3 Years
- Steven R. Sarkisian, MD Safety of the Surgical Exchange
Procedure of Travoprost Intraocular Implant
- I. Paul Singh, MD Travoprost Intraocular Implant
Demonstrates Noninferiority to Twice-Daily Timolol 0.5% in Lowering
IOP
Key Corneal Health Presentations:
Friday, November 3, 2023, at 1:53 p.m. PT
- Theo Guenter Seiler, MD Innovations in Collagen
Cross-Linking
Key Corneal Health Posters:
- Julia Yu Dynamics of Corneal Swelling During Hypotonic
Riboflavin in Corneal Collagen Cross-Linking for Progressive
Keratoconus Patients
Abstract information can be found at
www.aao.org/annual-meeting.
The AAO Annual Meeting is among the largest gatherings of
ophthalmic physicians, medical personnel, and industry executives
in the ophthalmic industry. All educational content of the AAO
Annual Meeting is planned by its program committee, and AAO does
not endorse, promote, approve or recommend the use of any products,
devices or services.
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic medical technology
and pharmaceutical company focused on developing and
commercializing novel therapies for the treatment of glaucoma,
corneal disorders and retinal diseases. Glaukos first developed
Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the
traditional glaucoma treatment paradigm, launching its first MIGS
device commercially in 2012, and continues to develop a portfolio
of technologically distinct and leverageable platforms to support
ongoing pharmaceutical and medical device innovations. Products or
product candidates for each of these platforms are designed to
advance the standard of care through better treatment options
across the areas of glaucoma, corneal disorders and retinal
diseases.
About iStent inject® W Trabecular Micro-Bypass System
(U.S.)
Indication for Use: The iStent inject W Trabecular Micro-Bypass
System Model G2-W is indicated for use in conjunction with cataract
surgery for the reduction of intraocular pressure (IOP) in adult
patients with mild to moderate primary open-angle glaucoma.
Contraindications: The iStent inject W is contraindicated in
eyes with angle-closure glaucoma, traumatic, malignant, uveitic, or
neovascular glaucoma, discernible congenital anomalies of the
anterior chamber (AC) angle, retrobulbar tumor, thyroid eye
disease, or Sturge-Weber Syndrome or any other type of condition
that may cause elevated episcleral venous pressure.
Warnings: Gonioscopy should be performed prior to surgery
to exclude congenital anomalies of the angle, PAS, rubeosis, or
conditions that would prohibit adequate visualization of the angle
that could lead to improper placement of the stent and pose a
hazard.
MRI Information: The iStent inject W is MR-Conditional, i.e.,
the device is safe for use in a specified MR environment under
specified conditions; please see Directions for Use (DFU) label for
details.
Precautions: The surgeon should monitor the patient
postoperatively for proper maintenance of IOP. The safety and
effectiveness of the iStent inject W have not been established as
an alternative to the primary treatment of glaucoma with
medications, in children, in eyes with significant prior trauma,
abnormal anterior segment, chronic inflammation, prior glaucoma
surgery (except SLT performed > 90 days preoperative), glaucoma
associated with vascular disorders, pseudoexfoliative, pigmentary
or other secondary open-angle glaucomas, pseudophakic eyes, phakic
eyes without concomitant cataract surgery or with complicated
cataract surgery, eyes with medicated IOP > 24 mmHg or
unmedicated IOP < 21 mmHg or > 36 mmHg, or for implantation
of more or less than two stents.
Adverse Events: Common postoperative adverse events reported in
the iStent inject randomized pivotal trial included stent
obstruction (6.2%), intraocular inflammation (5.7% for iStent
inject vs. 4.2% for cataract surgery only), secondary surgical
intervention (5.4% vs. 5.0%) and BCVA loss ≥ 2 lines ≥ 3 months
(2.6% vs. 4.2%).
Caution: Federal law restricts this device to sale by, or on the
order of, a physician. Please see DFU for a complete list of
contraindications, warnings, precautions, and adverse events.
For more information, visit www.glaukos.com.
iDose® TR is an investigational therapy and is not currently
approved by the FDA.
Forward-Looking Statements
All statements other than statements of historical facts
included in this press release that address activities, events or
developments that we expect, believe or anticipate will or may
occur in the future are forward-looking statements. Although we
believe that we have a reasonable basis for forward-looking
statements contained herein, we caution you that they are based on
current expectations about future events affecting us and are
subject to risks, uncertainties and factors relating to our
operations and business environment, all of which are difficult to
predict and many of which are beyond our control, that may cause
our actual results to differ materially from those expressed or
implied by forward-looking statements in this press release. These
potential risks and uncertainties include, without limitation, the
timing and extent to which obtain regulatory approval for
investigational products, our ability to successfully commercialize
such products, the ability to obtain and maintain adequate
financial coverage and reimbursement for our products, and the
continued efficacy and safety profile of our products as might be
suggested in the presentations at the AAO meeting. These and other
risks, uncertainties and factors related to Glaukos, and our
business are described in detail under the caption “Risk Factors”
and elsewhere in our Quarterly Report on Form 10-Q for the quarter
ended June 30, 2023, which was filed with the Securities and
Exchange Commission (SEC) on August 3, 2023. Our filings with the
SEC are available in the Investor Section of our website at
www.glaukos.com or at www.sec.gov. In addition, information about
the risks and benefits of our products is available on our website
at www.glaukos.com. All forward-looking statements included in this
press release are expressly qualified in their entirety by the
foregoing cautionary statements. You are cautioned not to place
undue reliance on the forward-looking statements in this press
release, which speak only as of the date hereof. We do not
undertake any obligation to update, amend or clarify these
forward-looking statements whether as a result of new information,
future events or otherwise, except as may be required under
applicable securities law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231031263484/en/
Media Contact – Glaucoma: Stefanie Tuck (978) 390-1394
stefanie@jpa.com
Media Contact – Corneal Health: Michele Gray (917) 449-9250
michele@mgraycommunications.com
Investor Contact: Chris Lewis Vice President, Investor Relations
& Corporate Affairs (949) 481-0510 clewis@glaukos.com
Glaukos (NYSE:GKOS)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Glaukos (NYSE:GKOS)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024